Abstract :

For many years, cancer has affected the global population from an economic, social and political point of view and, in most cases, it is a malignant tumor with serious consequences for patients. The objective of this study is to answer the potential biomarkers for the diagnosis and prognosis of acute myeloid leukemia. Therefore, this is an exploratory, descriptive bibliographic study with a qualitative approach. The data were collected from a bibliometric survey carried out during a study of scientific production on the proposed topic from 2013 to 2023. After searching for articles, 210 articles were found on the PubMed platform, and no results were found for the key suggested by word in other databases. Among the 210 articles, 28 articles were selected for review. In this way, we seek to analyze which biomarkers have been addressed in the last 10 years in the scientific literature, thus aiming to demonstrate possible targets for new research. We divide our research into genes that are promising biomarkers for diagnosis and/or prognosis and the role of miRNAs as biomarkers.

---

Keywords :

Acute myeloid leukemia, Biomarkers, diagnosis, neoplasm genes, Screening., tumor biomarker

---

References :

1. José Alencar Gomes da Silva National Cancer Institute . 2020 estimate: incidence of cancer in Brazil / José Alencar Gomes da Silva National Cancer Institute. – Rio de Janeiro: INCA, 2019
2. Cirolini Oliveira, C., Quintana Castro, C., & Hörner, R. (2021). Epidemiological profile of patients with acute myeloid leukemia: An integrative review. Health (Santa Maria), 47(1). https://doi.org/10.5902/2236583464519
3. RUBNITZ, JE; GIBSON, B.; SMITH, FO Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America , vol. 24, no. 1, p. 35–63, Feb. 2010.
4. Ministry of Health. SECRETARIAT OF HEALTH CARE. ORDINANCE No. 705, OF AUGUST 12, 2014. DIAGNOSTIC AND THERAPEUTIC GUIDELINES ADULT ACUTE MYELOID LEUKEMIA https://bvsms.saude.gov.br/bvs/sas/Links%20finalizados%20SAS%202014/prt0705_12_08_2014.html
5. MELO, AN Oncology Observatory» Leukemia mortality trends in Brazil. Available at: <https://observatoriodeoncologia.com.br/mortalidade_leukemias/>.
6. BY CASSIA ROSA DE JESUS, J. .; ROCHA OLIVEIRA, CJ Tumor molecular markers. Brazilian Journal of Biomedical Sciences , [S. l.] , v. 1, no. 1, p. 43, 2020. DOI: 10.46675/rbcbm.v1i1.8. Available at: https://rbcbm.com.br/journal/index.php/rbcbm/article/view/8. Accessed on: 2 Nov. 2023.
7. GAYON, J. From Mendel to epigenetics: History of Genetics. Comptes Rendus Biologies , v. 339, no. 7-8, p. 225–230, Jul. 2016.
8. SASAKI, K. et al. Impact of the variant allele frequency ofASXL1,DNMT3A,JAK2,TET2,TP53, andNPM1on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer , vol. 126, n. 4, p. 765–774, 19 Nov. 2019.
9. CALIFF, RM Biomarker Definitions and Their Applications . Experimental Biology and Medicine , vol. 243, n. 3, p. 213–221, Feb. 2018.
10. ‌CONCEPCIÓN PRATS‐MARTÍN et al. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype . Cancer Medicine , vol. 9, no. 11, p. 3637–3646, 26 Mar. 2020.
11. ZHAO, N. et al. [Prediction of outcome in acute myeloid leukemia by measurement of WT1 expression as a basic marker of minimal residual disease] . Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, v. 38, no. 8, p. 695–699, 14 Aug. 2017.
12. HUANG, Q.-S. et al. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia . Blood Advances , vol. 3, no. 21, p. 3406–3418, 12 Nov. 2019.
13. CHEN, C. et al. Higher Expression of WT1 With Lower CD58 Expression May be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia . Technology in Cancer Research & Treatment , vol. 20, p. 153303382110521-153303382110521, 1 Jan. 2021.
14. GOEL, H. et al. Molecular update on biology of Wilms Tumor 1 gene and its applications in acute myeloid leukemia . American Journal of Blood Research , vol. 10, no. 5, p. 151–160, 2020.
15. ‌UJJ , Z. et al. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors . Pathology & Oncology Research , vol. 22, no. 1, p. 217–221, 4 Nov. 2015.
16. ‌JIANG , X. et al. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition inFLT3-Mutant Acute Myeloid Leukemia. Clinical Cancer Research , vol. 24, no. 10, p. 2417–2429, 20 Feb. 2018.
17. ‌CANDONI , A. et al. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Experimental Hematology , vol. 49, p. 25–33, May 2017.
18. WEN , X. et al. Association Analyzes of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia. Frontiers in Immunology , vol. 12, 21 Oct. 2021.
19. ‌ KNAUS , HA et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy . JCI Insight , vol. 3, no. 21, 2 Nov. 2018.
20. Xie, J. et al. Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia . Current Research in Translational Medicine, vol. 70, no. 4, p. 103347, 1 set. 2022.
21. KOJIMA, K.; ISHIZAWA, J.; ANDREEFF, M. P harmacological activation of wild-type p53 in the therapy of leukemia . Experimental Hematology , vol. 44, no. 9, p. 791–798, 1 Sept. 2016.
22. ‌CHEN , S. et al. Bioinformatics Analysis Identifies Key Genes and Pathways in Acute Myeloid Leukemia Associated with DNMT3A Mutation. BioMed Research International , vol. 2020, p. 1–12, 23 Nov. 2020.
23. ‌JOST , E. et al. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia , vol. 28, no. 6, p. 1227–1234, 27 Nov. 2013.
24. JIN , H. et al. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia. Journal of Experimental & Clinical Cancer Research , vol. 37, no. 1, 17 Jan. 2018.
25. IBRAHEEM, FM et al. SALL4 Gene Expression in Acute Myeloid Leukemia . Asian Pacific Journal of Cancer Prevention, vol. 20, no. 10, p. 3121–3127, 1 Oct. 2019.
26. OELLERICH, T. et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML . Nature Communications , vol. 10, no. 1, p. 3475, 2 Aug. 2019.
27. TRINO, S. et al. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia . International Journal of Molecular Sciences , vol. 19, no. 2, p. 460, 3 Feb. 2018.
28. LIM , EL et al. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia . Journal of Clinical Oncology , vol. 35, no. 35, p. 3964–3977, 10 Dec. 2017.
29. ‌YAN , W. et al. MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model . Oncotarget , vol. 6, no. 28, p. 26424–26436, 1 Jul. 2015.
30. ZHOU, J. et al. MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia . Aging, vol. 11, no. 10, p. 3376–3391, 30 May 2019.
31. GADO, MM et al. Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia . Asian Pacific journal of cancer prevention: APJCP , v. 20, no. 12, p. 3625–3633, 1 Dec. 2019.